Abstract. Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide with poor prognosis due to resistance to conventional chemotherapy and limited efficacy of radiotherapy. Thus, alternative therapeutic strategies need to be established. In order to search for a useful biomarker to improve its efficacy, we conducted a two-dimensional gel electrophoresis and MALDI-TOF MS-based comparative proteomic analysis to profile the differentially expressed proteins between HCC tumor tissues with histological evidence and the adjacent non-tumor tissues. Twenty-two out of 43 dysregulated proteins were identified, including 15 upregulated proteins, and 7 downregulated proteins (over 2-fold, P<0.01). The expression of peroxiredoxin 3 (PRDX3) at the mRNA and protein levels was confirmed by RT-PCR and western blotting in HCC cell lines, and HCC samples, and further analysed by immunohistochemistry in HCC samples of different clinical pathological stages. The results indicated that overexpression of PRDX3 was associated with 94.9% HCC, and correlated with poor differentiation (P<0.05), which suggest that PRDX3 has substantial clinical impact on the progression of hepatocarcinoma, and may be a potential therapeutic target for HCC.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide with poor prognosis due to limited efficacy of radiotherapy and resistance to traditional chemotherapy (1) . Chronic infection with hepatitis B or C virus has been thought as the major etiologic factor, accounting for about 80% of all HCC cases. Due to a high frequency of metastasis/ recurrence, 5 year survival rate is less than 30%, and about one-third of the HCC patients relapse within 1 year after curative surgery (2, 3) . Many potentials for clinical therapy in HCC have been identified, however, most of them were not particularly efficient in treating HCC. Consequently, there is an urgent need to screen for novel biomarkers and therapeutic targets with high sensitivity, specificity and operability.
Proteomics approaches are promising tools for the discovery of new tumor-associated biomarkers and therapeutic drug targets (4) . In addition to the better genetic and epigenetic alterations, there are other factors related to molecular changes in translation, post-translational modification, and intra cellular mislocalization involved in tumor initiation and growth, and these factors cannot be detected either by measuring the amount of RNA or by detecting nucleotide sequence variation (5) . By examining the expression abundance and post-translational modification of hundreds of proteins, and further comparative analysis of proteomes between different samples, proteomics can directly reveal the genetic information of many types of cancer. For comparative proteomics studies, two dimensional gel electrophoresis (2-DE) followed by mass spectrometry analysis is the core technology used in finding the differentially displayed proteins and identifying the novel biomarkers (6) . Biomarkers associated with the progression of cancer, such as glutathione S-transferase pi 1 (GSTP1), des-γ-carboxyprothrombin (DCP), and heat shock protein 27 (HSP 27) have been identified (7) (8) (9) , however, their application in clinical therapy is limited. In our present study, 22 differential proteins with a variety of biological functions were identified by Matrix-Assisted Laser Desorption/ Ionization Time of Flight Mass Spectrometry (MALDI-TOF MS). Among these, thioredoxin-dependent peroxide reductase, mitochondrial peroxiredoxin 3 (PRDX3) is of great interest due to its high expression in HCC.
Several investigations demonstrated that HCC was closely correlated to oxidative stress (10) . Cancer cells usually alter their key mitochondrial regulators of cell death and their mitochondrial structure and function is different from that of normal cells. This enables them to use antioxidant systems to maintain the redox balance under high oxidative stresses (11) . Classical antioxidant genes related to cancer are the superoxide dismutase (SOD), catalase, GST, glutathione peroxidase, peroxiredoxins and thioredoxin (Trx) (12) (13) (14) (15) (19) . PRDX3 has been shown to be overexpressed in mesothelioma, hepatocellular carcinoma, breast cancer and ovarian cancer (20) (21) (22) (23) , which suggest that PRDX3 may be involved in tumorigenesis and progression.
In the present study, we analyzed the differential proteome profiles between HCC and adjacent non-tumor tissues to identify the potential molecules as tumor therapeutic targets. We identified 15 upregulated and 7 downregulated proteins with various of biological functions by MALDI-TOF/TOF tandem mass spectrometry. PRDX3, which was significantly upregulated in HCC tissues compared with the adjacent non-tumor tissues, was chosen for validation and analysis. Clinical correlation of PRDX3 with different clinicopathological features in HCC was also evaluated. The data presented in this study demonstrates that overexpression of PRDX3 is closely associated with the progression of hepatocarcinoma, and targeting PRDX3 may inhibit malignant transformation and progression. These findings have potential therapeutic implications.
Materials and methods
Cell lines and clinical specimens. Human hepatoma HepG2, Hep3B, QGY-7703, HuH7 cell lines and the normal liver cell line QSG-7701 were obtained from the American Type Culture Collection (ATCC). All cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM) (Gibco, USA) containing 10% fetal bovine serum (Gibco), 100 U/ml of penicillin, and 100 µg/ml of streptomycin in a humidified incubator at 37˚C with 5% CO 2 .
For proteomics analysis, 27 pairs of human frozen HCC histologically-confirmed tissues and the adjacent non-tumor tissues were obtained from the Department of Surgery, Third Xiangya Hospital of Central South University. Informed consent was obtained from each patient. Tissues were snapfrozen in liquid nitrogen after surgical resection and stored at -80˚C until use. For the validation studies, 119 HCC tissue samples and 36 adjacent non-tumor/normal liver specimens were obtained between the years 2009 and 2011. A summary of clinical information for these patients is shown in Table II .
Protein extraction and 2-DE proteomics profiling.
Proteins from tumor and matched non-tumor tissues were extracted using the ReadyPrep Sequential Extraction kit (Bio-Rad, USA) according to the manufacturer's protocol. Samples were cleaned up using a PlusOne 2-D Clean-up kit (GE Healthcare, USA), and dissolved with sample buffer [7 M urea, 2 M thiourea, 4% CHAPS, 1% Mega-10, 0.5% Triton X-100, 1% IPG buffer (pH 4-7)], 50 mM dithiothreitol and 2 mM tributylphosphine). Proteins of 150 µg from tumor and non-tumor tissues were separately mixed with rehydration buffer [7 M urea, 2 M thiourea, 4% CHAPS, 0.5% IPG buffer (pH 4-7)] followed by rehydration for 12 h at 30 V using the Immobiline IPG DryStrips (18 cm, pH 4-7) (GE Healthcare), and then were isoelectrically focused at 500 V for 1 h, 1,000 V for 1 h, 3,000 V for 1 h and 8,000 V for 9.5 h on an Ettan IPGphor Electrophoresis system (GE Healthcare). After equilibration for 2x15 min in equilibration buffer, IPG strips were applied for 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using a PROTEAN ® II xi Cell system (Bio-Rad). Each sample was run in triplicate.
Image acquisition and analysis. The gels were stained using Coomassie Brilliant Blue R-350 (Amersham Biosciences) according to the manufacturer's protocol. The protein spots were detected, quantified, and matched using PD-Quest 2D analysis software (Bio-Rad). Differences in the expression levels between paired samples were analyzed by the Student's t-test. Protein spots showing at least 2-fold changes in intensity were picked for trypsin digestion and MALDI-TOF MS analysis.
In-gel tryptic digestion and protein identification by mass spectrometry. The protein spots were excised from the gel and subjected to destaining, washing, and trypsin digestion (Promega) at 37˚C overnight. The tryptic peptides were extracted from the gel and dried by centrifugal lyophilization. Peptide mixtures were redissolved in 0.5% TFA and analyzed by an ABI 4700 proteomics analyzer (Applied Biosystems, USA). Protein identification was performed using the Mascot software (Matrix Science, UK) and all tandem mass spectra were searched against the Swiss-Prot protein database. The search parameters included potential residue mass modification for carbamidomethylation and oxidation, one missed trypsin cleavage, and fragment ion tolerance and peptide tolerance of ±0.2 Da. Up to one missed tryptic cleavage was considered for all tryptic-mass searches. Protein scores >56 were considered to be significant (P<0.05). Redundancy of proteins that appeared in the database under different names and accession numbers was eliminated. If more than one protein was identified in one spot the single protein member with the highest protein score was singled out from the multiprotein family.
Reverse transcriptase-polymerase chain reaction (RT-PCR).
Total-RNA was extracted from frozen liver tissues or cell lines HepG2, QSG-7701 using TRIzol reagent following the manufacturer's instructions (Invitrogen, USA). RT-PCR was used for the analysis of human PRDX3 mRNA with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as an internal control. The following primer sequences were used to detect PRDX3 transcripts: forward primer, 5'-TGGTTCCAGTCAAGCAA AAT-3' and reverse primer, 5'-AACCTTCTAACAGCACACC GT-3'. The GAPDH primers were as follows: forward, 5'-TG ATGACATCAAGAAGGTGGTGAAG-3' and reverse, 5'-TC CTTGGAGGCCATGTGGGCCAT-3'. Reactions were performed in accordance with the standard protocol. PCR was performed initially by reverse transcription at 42˚C for 60 min and denaturation at 95˚C for 2 min, then amplification for 35 cycles at 94˚C for 30 sec, annealing at 55˚C for 30 sec, and extension at 72˚C for 30 sec, followed by a terminal elongation step at 72˚C for 10 min. PCR products were analyzed by electrophoresis through 1.5% agarose and visualized with ethidium bromide. Experiments were performed in triplicate.
Western blot analysis. Total proteins of 50 µg from frozen liver tissues or cell lines HepG2, Hep3B, QGY-7703, HuH7, and QSG-7701 were separated by 12% SDS-PAGE and transferred onto poly-vinylidene difluoride (PVDF) membranes (Amersham Biosciences). The detection of proteins was carried out by incubating the membranes with anti-PRDX3 monoclonal antibody (diluted 1:1,000, Abcam) or mouse anti-human β-actin antibody (Santa Cruz Biotechnology, Inc., USA) at 1:1,000 dilution overnight at 4˚C and followed by peroxidase-conjugated secondary antibody (Invitrogen). After substrate development by ECL chemiluminescence (GE Healthcare), signal intensity was quantitatively analyzed using the Quantity One software (Bio-Rad).
Immunohistochemistry. Consecutive formalin-fixed and paraffin-embedded tissue sections (3-5 µm) for immunohistochemistry (IHC) analysis were dewaxed and rehydrated. Antigen retrieval was performed by pretreatment of the slides in citrate buffer (pH 6.0) in a microwave oven for 15 min. Endogenous peroxidase activity was quenched by incubating the slides in methanol containing 0.6% H 2 O 2 at room temperature. For PRDX3-specific staining, the sections were blocked by normal goat serum for 1 h at 37˚C, and subsequently, incubated with anti-human PRDX3 antibody (diluted 1:100, Abcam) at 4˚C overnight, and rinsed with PBS containing 0.1% bovine serum albumin. Incubation with horseradish peroxidase-linked goat anti-mouse antibodies at 37˚C for 30 min was followed by reaction with 3,3'-diaminobenzidine substrate solution and counterstaining with Mayer's hematoxylin.
The immunohistochemical staining was assessed by calculating the percentage of positive hepatocytes and the immunostaining intensity. Immunostaining intensity (i) was classified as lack of staining, 0; mild staining, 1; moderate staining, 2; and strong staining, 3. The percentage of stainingpositive stroma (ii) was semiquantitatively divided into five grades: <5%, 0; 6-25%, 1; 26-50%, 2; 51-75%, 3; and >75%, 4. The score for each section was measured as (i) x (ii), and the result was defined as negative (-, 0), weakly positive (+, 1-3), positive (++, 4-7), and strongly positive (+++, [8] [9] [10] [11] [12] . A minimum of five fields for each section were evaluated. Slides were examined separately by two independent pathologists without any prior knowledge of each patient's clinical and pathological parameters. Any discrepancy between the two evaluators was resolved by reevaluation and careful discussion until agreement was reached.
Statistical analysis. Statistical analyses were performed by SPSS 13.0 software. All data are expressed as mean ± SD. Comparisons among multiple groups were performed by one-way ANOVA, or LSD t-test. Difference between two groups were analyzed by the LSD t-test. Relevance analysis of ordinal data was analyzed by the cross-tabulation χ 2 test. P-value <0.05 was considered statistically significant. Mass spectrum identification and functional classification of differentially expressed proteins. After MALDI-TOF/ TOF tandem mass spectrometry analysis and Swiss-Prot database search, 22 proteins identified from 43 spots (Table I) . Of these proteins, 15 were upregulated, whereas the other 7 were downregulated in HCC. To understand the biological relation of the identified molecules with the progression of HCC, the identified 22 proteins were classified according to their biological functions with the tools on www.uniprot. org (Table I) . These proteins were functionally involved in diverse biological processes, including metabolism (9/22, 40.9%), anti-apoptosis (4/22, 18.2%), signal transduction (7/22, 31.8%), redox regulation (5/22, 22.7%), structural protein (3/22, 13,6%), detoxification (2/22, 9.1%), chaperone (3/22, 13.6%), proteolysis (1/22, 4.5%), DNA synthesis and cell differentiation (2/22, 9.1%). Of the 22 proteins, 13 (59.1%) were cytoplasmic, 2 (9.1%) were cytoplasmic and nuclear, 2 (9.1%) were membranous, 4 (18.2%) were mitochondrial, and 1 (4.5%) was a secreted protein (Table I) .
Results

Proteomic profiling of differentially expressed proteins
Most of these identified proteins had been reported elsewhere and their role in the progression of HCC is clearly understood. PRDX3 plays important roles in the regulation of cellular redox balance, and may be involved in the progression Figure 1 . Differential proteomics analysis of HCC and the adjacent non-tumor tissues using 2-DE gels. Total protein lysates were separated by isoelectric focusing (IEF) using IPG strips (18 cm, pH 4-7) in the first dimension followed by 12% SDS-PAGE in the second dimension. Coomassie-stained gels were analyzed using the PD-Quest 2D analysis software. Totally, 22 out of 43 differentially expressed spots were identified by MS/MS analysis (marked with arrows and numbers). 3E and F) . Western blot analysis was performed using an anti-PRDX3 antibody. The overall expression levels in the tumor tissues (0.82±0.13) were higher than those in the matched non-tumor tissues (0.52±0.09) (Fig. 3D) , which was consistent with the results of the cell lines. These results confirmed that higher levels of PRDX3 were expressed in HCC or hepatoma cell lines compared with non-tumor tissues or normal liver cell line at both the mRNA and protein levels (Fig. 3) . Also, expression levels of PRDX3 are shown to be case-dependent and higher mRNA (0.83±0.24) and protein levels (0.86±0.21) of PRDX3 were found in HCC with distant metastasis (data not shown). These results showed that the increasing trend paralleled the increasing severity of liver injury.
Overexpression of PRDX3 is correlated with poor differentiation of HCC.
To investigate the oncogenic properties of PRDX3 in the progression of HCC, paraffin-embedded tissues were stained using anti-human PRDX3 antibody. HCC tissues (n=119) at different clinicopathologic stages and adjacent non-tumor/normal liver tissues (n=36) were prepared for immunohistochemical analysis. Of the 119 HCC samples, 27 were well differentiated, 74 were moderately differentiated, and 18 were poorly differentiated; 17 were in stage I, 56 were in stage II, 42 were in stage III, and 4 were in stage IV according to histodifferentiation criteria/TNM staging (Table II) .
Staining for PRDX3 was mainly detected in the HCC cells (Fig. 4) . In 36 adjacent non-tumor/normal specimens, no staining and weakly positive staining were detected in 17 and 83% of the samples, respectively. By contrast, in tumor tissues, weakly-positive staining was observed in 5.0% (6/119), moderately positive staining in about 61.3% (73/119) and the strong positive staining in 33.7% (40/119) ( Table II) . The staining intensity and the number of positively stained cells were markedly different between non-tumor tissues and hepatoma tissues (P<0.01) (Fig. 4) . Overexpression of PRDX3 was more likely to occur in poorly-differentiated tissues (P<0.05). Table I 
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Discussion
The mortality rate of HCC has remained relatively high for many years, and its efficacy is limited (24) . Therefore, identification of novel tumor biomarkers with higher specificity and sensitivity for the treatment of HCC has the potential to improve the clinical strategy and outcome of HCC.
In the present study, to identify potential biomarkers, comparative proteomic profiling analysis on matched tumor and nontumor tissues identified 22 differentially expressed proteins. Among these, 15 were upregulated, whereas the other 7 were downregulated in HCC. They were classified into several functional groups including metabolism, signal transduction, anti-apoptosis, and redox regulation. (Table I) . These proteins could be functionally interrelated to important cellular events, such as cell energy metabolism, antioxidation, cell proliferation, which have been related to the tumorigenesis and progression of malignancies.
PRDX3 belongs to the peroxiredoxin protein family (Prx), which was identified as a cellular defense system against oxidative stress and whose catalytic activity and protein sequences are different from that of other antioxidants (15) . As a mitochondrial protein and a c-Myc target gene, PRDX3 catalyzes the reduction of peroxides in the presence of thioredoxin, which is required for mitochondrial homeostasis and neoplastic transformation (17) . PRDX3 is an important cellular antioxidant that regulates physiological levels of H 2 O 2 stress to protect cells against apoptosis induced by high levels of H 2 O 2 (25). Basu et al (26) have shown that PRDX3 is overexpressed in prostate cancer and could be a potential biological determinant of health disparities of patients and novel therapeutic targets. Furthermore, downregulation of PRDX3 could be a possible apoptotic pathway for PP2-induced apoptosis in breast cancer of MCF-7 cells (27) . In addition, the overexpression of PRDX3 had also been found in cervical cancer, colorectal cancer and ovarian serous cystadenocarinoma. (25, 28, 29) . However, there are few reports on the relationship between PRDX3 and the progression of HCC, and thus, we focused on the study of thioredoxin-dependent peroxide reductase PRDX3. PRDX3 was found to be upregulated more than 3-fold in HCC tissues, and its differential expression was further verified by RT-PCR and western blotting in a panel of HCC tissues. From our study, we observed that expression of PRDX3 in HCC tissues was higher than that in non-tumorigenic tissues, which was consistent with the results of cell lines (Fig. 3) . A higher expression of PRDX3 was observed in metastatic HCC tissues, indicating that PRDX3 may be an important molecule in the development of HCC.
To further study the potential role of PRDX3 as a biomarker for tumor progression, we examined the correlations between PRDX3 expression and HCC staging and histodifferentiation. Our clinicopathological analysis indicated that overexpression of PRDX3 was associated with 94.9% HCC, and strongly correlated with poor differentiation (P<0.05). Our studies suggested that PRDX3 has the potential to be developed as a useful biomarker for the therapy of HCC.
In the induction and progression of HCC, reactive oxygen species (ROS) play a critical role (30) . Cancer cells are known to have higher levels of intracellular ROS because of increased cellular respiration. High levels of free radicals are thought to have the potential to oxidize macromolecules and thereby to induce mutation of DNA, impairment of protein function, and lipid peroxidation, which lead to tumor development (31) . Several studies have shown that tumor cells become more resistant to hypoxia or oxidative stress-induced cell death during carcinogenesis (32) .
Increased mitochondrial ROS generation and the disturbance of peroxiredoxin (Prx) production in cancer cells may lead to oxidative stress and hypoxic microenvironments, and subsequently to the induction of apoptosis (17) . The upregulation of antioxidant enzymes, especially in mitochondria, would provide the tumor cells with certain survival advantages under their intrinsically high oxidative conditions (31) . To protect against oxidative stress induced by ROS, cells use several antioxidants or reductants to maintain the intracellular redox environment in a highly reduced state (33) . Therefore, increased expression levels of PRDX3 were assumed to protect tumor cells against the hypoxia microenvironment and drug-induced hydrogen peroxide-dependent apoptosis. Data presented in this study suggest that malignant cells are usually under intrinsic oxidative stress and produce high levels of ROS. Thus, inhibiting mitochondrial antioxidant enzymes in malignant cells may act as an effective cancer therapeutic method.
In conclusion, we analyzed the comparative proteomic profiles between HCC tumors and adjacent non-tumor tissues by 2-DE and MALDI-TOF MS, and identified differentially expressed molecules which may help to develop effective therapeutic strategies against HCC. PRDX3 was found and confirmed to predict the poor differentiation of HCC based on proteomics screening and molecular biology confirmation. The results of our study suggest that PRDX3 has substantial clinical impact, but more extensive investigations on the role of PRDX3 in the progression of HCC are warranted.
